QuellTX Logo

News

PAGE:
1 2 3
19/10/21

Quell Therapeutics Presents New Data Demonstrating the Ability of its Proprietary Phenotype Lock Technology to Enhance the Safety, Stability and Efficacy of Engineered Treg Therapies

Quell’s phenotype lock technology is a core element of its multi-modular engineered Treg platformLocks Treg cells in a potently suppressive phenotype and prevents switch to potentially pathogenic effector phenotypesPreclinical data presented at the European Society of Gene & Cell Therapy…...

Read More
23/09/21

Quell Therapeutics Significantly Expands Clinical Manufacturing Capacity for its Engineered Treg Cell Therapies through a Collaboration with the Cell and Gene Therapy Catapult

Collaboration to facilitate an expanded manufacturing footprint to enable clinical supply of Quell’s pipeline, including QEL-001 in liver transplantation and pipeline programs in neuroinflammation and autoimmunity  London, UK – September 23, 2021 – Quell Therapeutics Ltd (“Quell”), the world leader…...

Read More
04/08/21

Quell Therapeutics to Present at the 2021 Wedbush Pacgrow Healthcare Virtual Conference

London, UK and Boston, MA, USA, August 4, 2021 – Quell Therapeutics Ltd (“Quell”), the world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that Iain McGill, Chief Executive…...

Read More
29/07/21

Quell Therapeutics Appoints Tracey Lodie, Ph.D., as Chief Scientific Officer

Dr. Hartl, former Therapeutic Area Head – Autoimmunity/Transplantation/Inflammation at Novartis Institutes for Biomedical Research (NIBR), to lead Quell's innovative multi-modular Treg cell therapy programs into clinical development LONDON and BOSTON, July 29, 2021 - Quell Therapeutics Ltd ("Quell"), the world leader in developing engineered…...

Read More
29/07/21

Quell Therapeutics Appoints Dominik Hartl, M.D., as Chief Medical Officer

Dr. Hartl, former Therapeutic Area Head – Autoimmunity/Transplantation/Inflammation at Novartis Institutes for Biomedical Research (NIBR), to lead Quell's innovative multi-modular Treg cell therapy programs into clinical development LONDON, July 22, 2021 /PRNewswire/ -- Quell Therapeutics Ltd ("Quell"), the world leader in developing engineered…...

Read More
06/04/21

BioCentury – Quell: tweaking Tregs for persistence, potency and stability

 London-based Quell is among a new generation of companies springboarding off advances in CAR T cells and gene editing to develop more targeted Treg cell therapies with enhanced persistence, potency and stability.  To view the full article please click here...

Read More
11/02/21

Quell Therapeutics Expands Series A Financing to $84 Million

– Largest Series A in the Treg field – – Lead program is a first-in-class treatment targeting liver transplantation with engineered Treg cell therapy – – First program expected to enter the clinic in first half of 2022 – London,…...

Read More
26/10/20

Quell Therapeutics Enters a Collaborative Research Agreement with the University of Sheffield

Collaboration will accelerate Quell’s pipeline expansion into neuroinflammatory diseases London and Sheffield, UK – October 26, 2020 – Quell Therapeutics, a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced that the company has entered into a collaborative…...

Read More
11/06/20

Quell Therapeutics strengthens its Board with the appointments of Dr Dhaval Patel and Sir Robert Lechler and hires Dr Natalie Belmonte as SVP Research & Translation

London – June 11 2020 – Quell Therapeutics, a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced the  appointments of seasoned industry expert, Dr Dhaval Patel, Executive Vice President and Chief Scientific Officer UCB S.A. (Brussels, Belgium),…...

Read More
PAGE:
1 2 3